Clinical Trials Directory

Trials / Completed

CompletedNCT00662857

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

A Phase 2, Open-Label, Randomized, 2-Way Crossover, Clinical Trial to Compare the Pharmacokinetics of 2 Formulations of "Intended Commercial Product" Technosphere® Insulin Inhalation Powder and to Determine the Bioavailability of a 30 Unit Cartridge of "Intended Commercial Product" Technosphere® Insulin Inhalation Powder Versus a 10 Unit Subcutaneous Injection of Insulin Lispro in Subjects With Type 1 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Mannkind Corporation · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue).

Detailed description

28 eligible subjects were planned to be enrolled to determine bioequivalence and safety parameters of two 15 U TI Inhalation Powder cartridges versus one 30 U TI Inhalation Powder cartridge, according to a randomized, 2-way crossover design. Additionally, bioavailability of one 30 U TI Inhalation Powder cartridge to a single subcutaneous injection of 10 IU of RAA will be compared.

Conditions

Interventions

TypeNameDescription
DRUGTechnosphere® Insulin Inhalation PowderTI Inhalation Powder, two 15 U cartridges
DRUGTechnosphere Insulin® Inhalation PowderTI Inhalation Powder, one 30 U cartridge
DRUGRAA PopulationRAA Population: All subjects received a single 10 IU sc injection of insulin lispro.

Timeline

Start date
2008-04-01
Primary completion
2008-11-01
Completion
2008-12-01
First posted
2008-04-21
Last updated
2014-10-16
Results posted
2014-10-16

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00662857. Inclusion in this directory is not an endorsement.